Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement

Mar

17

Today In Oncology

Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC

Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia

New Prostate Cancer Risk Classification With PSMA-PET

FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool

No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma

Advertisement

© 2026 HSP News Service, L.L.C.